Published in final edited form as:

Semin Nephrol. 2008 May ; 28(3): 289–296. doi:10.1016/j.semnephrol.2008.03.009.

Vasopressin and Aquaporin 2 (AQP2) in Clinical Disorders of Water Homeostasis

Robert W. Schrier

University of Colorado Health Sciences Center

The cloning of the V2 vasopressin receptor was a major advance in understanding the mechanisms involved in regulation of solute-free water excretion by arginine vasopressin (AVP) (1). Subsequently, mutations of the V2 receptor gene were found to account for approximately 85% of cases of congenital nephrogenic diabetes insipidus (2). The mechanisms whereby AVP activates the V2 receptor on the basolateral membrane of the principal cells of the collecting duct and leads to increased water permeability of the apical membrane were, however, quite perplexing. The water transport across the bilipid apical membrane of the principal cells was too fast to be due to diffusion alone. Thus, the shuttle hypothesis was proposed whereby theoretical water channels would be moved from the cytoplasm to the apical membrane of the principal cells by AVP (3). The discovery of the first water channel, aquaporin 1 (AQP1), by Agre and associates led to great excitement in the biomedical community and the awarding of the Nobel Prize in Chemistry in 2003 to Peter Agre (4). Subsequently, aquaporin 2 (AQP2) was identified by Sasaki et al. in the principal cells of the collecting duct (5). Further investigations have demonstrated that AVP is the major regulator of the AQP2 water channels (6). Activation of the V2 receptor on the principal cells of the collecting duct by AVP is associated with a cascade of events involving adenylyl cyclase-mediated cyclic AMP (Figure 1) (7) which leads to both short term and long term regulation of AQP2 (8,9). The short term regulation of AVP involves shuttling the AQP2 containing vesicles from the cytoplasm to the apical membrane. With suppression of vasopressin these apical AQP2 water channels then undergo endocytosis into the cytoplasm (3). The 5' flanking region of the AQP2 gene has a cyclic AMP response element which is involved in the long term upregulation of AQP2 protein expression by AVP (9).

The discovery of non-peptide antagonists to the V2 receptor have added yet another important dimension to the understanding of total body water homeostasis (10). These V2 receptor antagonists are agents that specifically block the action of AVP in humans. The several V2 receptor antagonists presently involved in clinical studies are shown in Table 1 (11). In contrast to diuretics, which enhance urine water and electrolyte excretion, the V2 receptor antagonists increase electrolyte-free water excretion.

A relative excess of total body water to cation concentration leads to hyponatremia in many clinical circumstances. In fact, hyponatremia is the most frequent electrolyte disturbance in hospitalized patients (12). V2 receptor antagonists have substantial clinical implications, since the majority of the hyponatremic states are due to the non-osmotic release of AVP (13). These V2 receptor antagonists have also been important vehicles to understand several water-

retaining states including cardiac failure, cirrhosis, and pregnancy, as well as thyroid and adrenal disorders. These disorders will be discussed in this review.

Cardiac Failure

Hyponatremia is common in patients with advanced cardiac failure and, in fact, pretreatment hyponatremia is a major risk factor for mortality in patients with congestive heart failure (14). The degree of hyponatremia and, thus, hypoosmolality in these patients would be expected to maximally suppress AVP in normal subjects. However, plasma AVP, as assessed by radioimmunoassay, is not maximally suppressed in hyponatremic patients with heart failure (15,16). If indeed baroreceptor-mediated, non-osmotic stimulation of vasopressin is responsible for the hyponatremia in cardiac failure, then the expression and membrane trafficking of AQP2 should be increased. Experimental studies in cardiac failure rats were, therefore, undertaken to examine this possibility (17,18). The results indeed demonstrated an upregulation of AQP2 protein expression and increased AQP2 trafficking to the apical membrane of principal cells of the collecting duct. Moreover, the excess water retention and hyponatremia in these heart failure animals was reversed by a V2 receptor antagonist (17). Subsequently, several studies with orally active, non-peptide V2 receptor antagonists have been shown in heart failure patients to enhance electrolyte-free water reabsorption and improve serum sodium concentration (19–21). AQP2 can be detected in the urine in the presence of AVP as a result of “spill over” into the nephron lumen from the apical membrane of collecting duct principal cells (22). In this regard, a V2 receptor antagonist was shown to decrease urinary AQP2 in heart failure patients (23).

The long term EVEREST study in heart failure patients demonstrated an early improvement in dyspnea (24) associated with long term safety (25). An effect to decrease mortality in heart failure patients with tolvaptan, a V2 receptor antagonist, was however not observed (26).

Cirrhosis

The renal regulation of sodium and water excretion resides primarily in the arterial circulation (26,27). Of total circulating blood volume, approximately 85% resides on the venous side of the circulation with the remaining 15% in the arterial circulation. Stretch arterial baroreceptors in the carotid artery, aortic arch, and glomerular afferent arterioles, sense arterial underfilling and activate the neurohumoral axis as a compensatory response to maintain arterial perfusion. In low-output cardiac failure this compensatory reflex is activated by a decrease in cardiac output. With cirrhosis, however, cardiac output is increased in the presence of continued sodium and water reabsorption and ascites formation. Early in cirrhosis, however, arterial vasodilation occurs in the splanchnic circulation secondary to portal hypertension (26). Arterial underfilling can occur by either a decrease in cardiac output or systemic arterial vasodilation, thereby activating the neurohumoral response including the non-osmotic release of AVP (Figure 2A and B) (28). Thus, both cardiac failure and cirrhosis exhibit arterial underfilling in spite of an increase in total blood volume secondary to expansion on the venous side of the circulation. The increase in cardiac output in cirrhotic patients occurs secondary to arterial vasodilation and the resultant decreased cardiac afterload.

On the background of this pathophysiology of cirrhosis, the non-osmotic stimulation of AVP should be involved in the excessive water retention and hyponatremia. Again, as with cardiac failure, pretreatment hyponatremia is a major risk factor for increased mortality in patients with advanced cirrhosis (29). Plasma AVP, as assessed by radioimmunoassay, has been shown not to be suppressed by an acute water load in hyponatremic cirrhotic patients (30). In advanced experimental cirrhosis, an upregulation of inner medullary AQP2 expression has been demonstrated (31). An increase in urinary AQP2 has also been found to be present in cirrhotic patients (32). Orally active V2 receptor antagonists have been used to treat hyponatremia in

cirrhotic patients (21,33). These studies have clearly shown that an enhanced electrolyte-free water excretion and an increase in plasma sodium concentration occur with V2 receptor antagonist administration in hyponatremic cirrhotic patients.

Pregnancy

Early in normal pregnancy plasma osmolality falls by about 10 mOsm/kg in association with an increase in thirst and water intake (34). Studies have shown that pregnancy is also a state of arterial underfilling secondary to systemic arterial vasodilation (35,36). In the presence of hypoosmolality plasma AVP is not suppressed and the renin-angiotensin-aldosterone axis is activated early in pregnancy. In pregnant rats inner medullary AQP2 is upregulated during the first trimester (Figure 3) (37) and a V2 receptor antagonist is associated with urinary dilution and increased electrolyte-free water excretion. Thus, pregnancy, as with cirrhosis, is another example in which arterial underfilling occurs secondary to systemic arterial vasodilation with the non-osmotic AVP stimulation and upregulation of AQP2 expression. In both cirrhosis and pregnancy there is evidence for a role of nitric oxide in mediating the arterial vasodilation (38,39).

Exogenous oxytocin is used to stimulate labor in pregnant women and can be associated with hyponatremia (40). This water-retaining effect of oxytocin has been shown in Brattleboro rats which have no detectable circulating AVP (41). In Brattleboro rats oxytocin increased AQP2 expression and trafficking to the apical membrane (42). Moreover, the antidiuresis and AQP2 effects were completely reversed by a V2 receptor antagonist. There was no effect of an oxytocin antagonist. The effect of oxytocin on electrolyte-free water excretion and AQP2 therefore appears to be primarily due to activation of the V2 receptor (43).

Hypo- and Hyperthyroidism

Patients with advanced primary hypothyroidism may be hyponatremic and fail to suppress plasma AVP with an acute water load (44). Advanced hypothyroidism may be associated with a decrease in blood pressure secondary to diminished myocardial contractability and heart rate. These hemodynamics are mimicked in hypothyroid rats and are reversed with thyroxin replacement (44). These impaired systemic hemodynamics would be expected to activate baroreceptor-mediated, non-osmotic AVP release and indeed this is the case. In this rat model of hypothyroidism the increase in plasma AVP was associated with upregulation of AQP2. Moreover, a V2 receptor antagonist has been shown in this rat model of hypothyroidism to reverse the increased AQP2 and the impaired response to an acute water load (Figure 4) (44). The hypothyroid rats also demonstrated a diminution in maximal urinary concentration which was associated with a defect in the counter-current concentrating mechanism (45). This defect was related to diminished maximal medullary osmolality and down-regulation of the co-transporter, NA-K-2Cl, which initiates the counter-current concentrating mechanism.

Hyperthyroid patients may exhibit polyuria (46) and this has also been shown to occur in the hyperthyroid rat (47). Somewhat surprising, however, this polyuria in the hyperthyroid rat is associated with an upregulation of Na-K-Cl transporter. The animals are, however, hypertensive and have an increase in solute excretion, even in the presence of control of water and food intake, most likely secondary to increased blood pressure and catabolism. The diminished urinary concentration and polyuria in hyperthyroid rats was associated with a down-regulation of AQP2 and a persistent solute diuresis (47). Both of these potential mediators of polyuria associated with hyperthyroidism may be related to the effect of the increase in blood pressure which has been shown to increase salt and water delivery to the distal nephron (48) and decreased AQP2 expression (49).

Glucocorticoid Deficiency and Mineralocorticoid Deficiency

The disorders of water homeostasis in glucocorticoid deficiency and mineralocorticoid deficiency appear to be mediated by different mechanisms (50,51). Both of these disorders exhibit hyponatremia associated with elevated plasma AVP concentrations. Mineralocorticoid deficiency is associated with renal salt wasting, extracellular fluid volume depletion, a decrease in cardiac output and blood pressure. In rats with mineralocorticoid deficiency these alterations are associated with water retention, hyponatremia and upregulation of AQP2 expression, effects that were totally reversed by avoidance of sodium depletion (52). In contrast, glucocorticoid deficiency is, if anything, mildly sodium retaining. A decrease in blood pressure, however, occurs secondary to diminished cardiac output and an impaired systemic vascular response to hypotension (53). The hyponatremia of hypopituitarism, i.e., selective glucocorticoid deficiency, can be reversed with physiological doses of hydrocortisone (54). In addition to the baroreceptor-mediated, non-osmotic AVP release secondary to hemodynamic alternations, there is also experimental evidence that glucocorticoid hormone is necessary for maximal suppression of vasopressin synthesis in the hypothalamus (55). In experimental selective glucocorticoid deficiency, the increase in plasma AVP was associated with an upregulation of vasopressin-mediated AQP2 water channels (56). V2 receptor antagonism was associated with reversal of the impaired water excretion and increase in AQP2 expression (Figure 5) (56). Thus, the impaired water excretion and hyponatremia with primarily adrenal insufficiency, i.e., Addison's disease, is due to both glucocorticoid and mineralocorticoid deficiency via non-osmotic stimulation of AVP but by different pathways.

In summary, much has been learned about the mechanisms of disorders of water homeostasis with the non-osmotic AVP stimulation and AQP2 upregulation playing a pivotal role in the defects in urinary dilution leading to hyponatremia. The urinary concentrating defects are more likely to involve defects in the counter-current concentrating mechanism such as down-regulation of Na-K-2Cl and diminished maximal medullary osmolality.

References

1. Birnbaumer M, Seibold A, Gilbert S, Ishido M, Barberis C, Antaramian A, Brabet P, Rosenthal W. Molecular cloning of the receptor for human antidiuretic hormone. *Nature* 1992;357:333–335. [PubMed: 1534149]
2. Sands J, Bichet D. Nephrogenic diabetes insipidus. *Ann Intern Med* 2006;144:186–194. [PubMed: 16461963]
3. Wade JB, Stetson DL, Lewis SA. ADH action: evidence for a membrane shuttle mechanism. *Ann NY Acad Sci* 1981;372:106–117. [PubMed: 6951416]
4. Agre P, Preston GM, Smith BL, Jung JS, Raina S, Moon C, Guggino WB, Nielsen S. Aquaporin CHIP: The archetypal molecular water channel. *Am J Physiol Renal Physiol* 1993;265:F463–F476.
5. Fushimi K, Uchida S, Hara K, Hirata Y, Marumo F, Sasaki S. Cloning and expression of apical membrane water channel of rat kidney collecting tubule. *Nature* 1993;361:549–552. [PubMed: 8429910]
6. Nielsen S, Frokiaer J, Marples D, Kwon T-H, Agre P, Knepper M. Aquaporins in the kidney: From molecules to medicine. *Physiol Rev* 2002;82:205–244. [PubMed: 11773613]
7. Bichet DG. Lithium, cyclic AMP signaling, A-kinase anchoring proteins, and aquaporin-2. *J Am Soc Nephrol* 2006;17:920–922. [PubMed: 16540556]
8. DiGiovanni S, Nielsen S, Christensen E, Knepper M. Regulation of collecting duct water channel expression by vasopressin in Brattleboro rats. *Proc Natl Acad Sci USA* 1994;91:8984–8988. [PubMed: 7522327]
9. Wade J, Nielsen S, Coleman R, Knepper M. Long-term regulation of collecting duct water permeability: freeze-fracture analysis of isolated perfused tubules. *Am J Physiol Renal Physiol* 1994;166:F723–F730.

10. Yamamura Y, Ogawa H, Yamashita H, Chihara T, Miyamoto H, Nakamura S, Onogawa T, Yamashita T, Hosokawa T, Mori T, et al. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. *Br J Pharmacol* 1992;105(4):787–791. [PubMed: 1387020]
11. Schrier RW. The sea within us: Disorders of body water homeostasis. *Curr Opin in Invest Drugs* 2007;8:304–311.
12. Hoorn EJ, Lindemans J, Zietse R. Development of severe hyponatraemia in hospitalized patients: Treatment-related risk factors and inadequate management. *Nephrol Dial Transplant* 2006;21:70–76. [PubMed: 16141458]
13. Schrier RW. Body water homeostasis: clinical disorders of urinary dilution and concentration. *J Am Soc Nephrol* 2006;17(7):1820–1832. [PubMed: 16738014]
14. Lee W, Packer M. Prognostic importance of serum concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. *Circulation* 1986;73:257–267. [PubMed: 3002660]
15. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. *N Engl J Med* 1999;341:577–585. [PubMed: 10451464]
16. Szatalowicz V, Arnold P, Chaimovitz C, Bichet D, Schrier RW. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. *N Engl J Med* 1981;305:263–266. [PubMed: 7242616]
17. Xu D, Martin P-Y, Ohara M, St. John J, Pattison T, Meng X, Morris K, Kim J, Schrier RW. Upregulation of aquaporin-2 water channel expression in chronic heart failure. *J Clin Invest* 1997;99:1500–1505. [PubMed: 9119993]
18. Nielsen S, Terris J, Andersen D, Ecelbarger C, Frokiaer J, Jonassen T, Marples D, Knepper M, Petersen J. Congestive heart failure in rats is associated with increased expression and targeting of aquaporin-2 water channel in collecting duct. *Proc Natl Acad Sci USA* 1997;94:5450–5455. [PubMed: 9144258]
19. Gheorghiade M, Gattis WA, O'Connor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: A randomized controlled trial. *JAMA* 2004;291:1963–1971. [PubMed: 15113814]
20. Abraham WT, Shamshirsaz AA, McFann K, Orem RM, Schrier RW. Aquaretic effect of lixivaptan, an oral non-peptide, selective V2 receptor vasopressin antagonist, in the New York Heart Association functional class II and III chronic heart failure patients. *J Am Coll Cardiol* 2006;47(8):1615–1621. [PubMed: 16630999]
21. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C for the SALT Investigators: Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. *N Engl J Med* 2006;355(20):2099–2112. [PubMed: 17105757]
22. Saito T, Ishikawa SE, Sasaki S, Nakamura T, Rokkuka K, Kawakami A, Honda K, Marumo F, Saito T. Urinary excretion of aquaporin-2 in the diagnosis of central diabetes insipidus. *J Clin Endocrinol Metab* 1997;82:1823–1827. [PubMed: 9177390]
23. Martin PY, Abraham WT, Xu L, Olson BR, Oren RM, Ohara M, Schrier RW. Selective V2 receptor vasopressin antagonism decreases urinary aquaporin-2 excretion in patients with chronic heart failure. *J Am Soc of Nephrol* 1999;10:2165–2170. [PubMed: 10505693]
24. Gheorghiade M, Konstam MA, Burnett JC, Grinfeld L, Maggioni AP, Swedberg K, Udelsion JE, Zannad F, Cook T, Ouyand J, Zimmer C, Orlandi C. Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. *JAMA* 2007;297:1332–1343. [PubMed: 17384438]
25. Konstam M, Gheorghiade M, Burnett J, Grinfeld L, Maggioni A, Swedberg K, Udelsion J, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C for the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure. *JAMA* 2007;297:1319–1331. [PubMed: 17384437]
26. Schrier RW. Body fluid volume regulation in health and disease: A unifying hypothesis. *Ann Int Med* 1990;113:155–159. [PubMed: 2193561]

27. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henricksen J, Rodes J. Peripheral arterial vasodilation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis. *Hepatology* 1988;8:1151–1157. [PubMed: 2971015]
28. Schrier RW. Decreased effective blood volume in edematous disorders: What does this mean? Editorial. *J Am Soc Nephrol* 2007;18(7):2028–2031.
29. Gines A, Escorsell A, Gines P, Salo J, Jimenez W, Inglada L, Navasa M, Claria J, Rimola A, Arroyo V, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. *Gastroenterology* 1993;105:229–236. [PubMed: 8514039]
30. Bichet D, Szatalowicz V, Chaimovitz C, Schrier RW. Role of vasopressin in abnormal water excretion in cirrhotic patients. *Ann Intern Med* 1982;96:413–417. [PubMed: 7065556]
31. Inoue T, Ohnishi A, Matsuo A, Kawai B, Kunihiro N, Tada Y, Koizumi F, Chau T, Okada Y, Yamamura Y, Tanaka T. Therapeutic and diagnostic potential of a vasopressin-2 antagonist for impaired water handling in cirrhosis. *Clin Pharmacol Ther* 1998;63:561–570. [PubMed: 9630829]
32. Ivarsen P, Frokiaer J, Aagaard N, Hansen E, Bendtsen F, Nielsen S, Vilstrup H. Increased urinary excretion of aquaporin 2 in patients with liver cirrhosis. *Gut* 2003;52:1194–1199. [PubMed: 12865281]
33. Gerbes AL, Gulerg V, Gines P, Decauz G, Gross P, Gandjini H, Dijan J. VPA Study Group. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: A randomized double-blind multicenter trial. *Gastroenterology* 2003;124:933–939. [PubMed: 12671890]
34. Briner V.; Cadnapaphornchai, M.; Schrier, RW. Chapt. 53, Hypertension and pregnancy. In: Schrier, RW., editor. *Diseases of the Kidney and Urinary Tract*. 8th ed. Philadelphia: Lippincott Williams and Wilkins; 2007. p. 1326-1350.
35. Chapman AB, Abraham WT, Zamudio S, Coffin C, Merouani A, Young D, Johnson A, Osorio F, Goldberg C, Moore LB, Dahms T, Schrier RW. Temporal relationships between hormonal and hemodynamic changes in early human pregnancy. *Kidney Int* 1998;54:2056–2063. [PubMed: 9853271]
36. Schrier RW, Briner VA. Peripheral arterial vasodilation hypothesis of sodium and water retention in pregnancy: Implications for pathogenesis of preeclampsia-eclampsia state. *Obstet Gynecol* 1991;77:632–639. [PubMed: 2002992]
37. Ohara M, Martin P-Y, Xu D-L, St. John J, Pattison T, Kim J, Schrier RWS. Upregulation of aquaporin 2 water channel expression in pregnant rats. *J Clin Invest* 1998;101:1076–1083. [PubMed: 9486978]
38. Martin PY, Gines P, Schrier RW. Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. *N Engl J Med* 1998;33:533–541. [PubMed: 9709047]
39. Cadnapaphornchai MA, Ohara M, Morris KG Jr, Knotek M, Rogachev B, Ladtkow T, Carter EP, Schrier RW. Chronic NOS inhibition reverses systemic vasodilation and glomerular hyperfiltration in pregnancy. *Am J Physiol Renal Physiol* 2001;280(4):F592–F598. [PubMed: 11249850]
40. Potter RR. Water retention due to oxytocin. *Obstet Gynecol* 1964;23:699–702. [PubMed: 14196398]
41. Lyness J, Robinson AG, Sheridan MN, Gash DM. Antidiuretic effects of oxytocin in the Brattleboro rat. *Experientia* 1985;41:1444–1446. [PubMed: 4065302]
42. Li C, Wang W, Summer S, Westfall T, Brooks D, Falk S, Schrier RW. Effect of oxytocin on water channel expression and trafficking in Brattleboro rats: Role of V2 receptor. *J Am Soc Nephrol*. In press.
43. Skowsky WR, Kikuchi TA. The role of vasopressin in the impaired water excretion of myxedema. *Am J Med* 1978;64:613–621. [PubMed: 645727]
44. Chen Y-C, Cadnapaphornchai MA, Yang J, Summer S, Falk S, Li C, Wang W, Schrier RW. Nonosmotic release of vasopressin and renal aquaporins in impaired urinary dilution in hypothyroidism. *Am J Physiol Renal Physiol* 2005;289:F672–F678. [PubMed: 15914774]
45. Chen Y-C, Cadnapaphornchai MA, Summer S, Falk S, Li C, Wang W, Schrier RW. Molecular mechanisms of impaired urinary concentrating ability in glucocorticoid-deficient rats. *J Am Soc Nephrol* 2005;16:2864–2871. [PubMed: 16107579]
46. Evered DC, Hayter CJ, Surveyor I. Primary polydipsia in thyrotoxicosis. *Metabolism* 1972;21:393–404. [PubMed: 4111512]
47. Wang W, Li C, Summer SN, Falk S, Schrier. Polyuria of thyrotoxicosis: Downregulation of aquaporin water channels and increased solute excretion. *Kidney Int*. 2007In press.

48. Schrier RW, De Wardener HE. Tubular reabsorption of sodium ion: influence of factors other than aldosterone and glomerular filtration rate 1. *N Engl J Med* 1971;285:1231–1243. [PubMed: 4939799]
49. Klein JD, Murrell BP, Tucker S, et al. Urea transporter UT-A1 and aquaporin-2 proteins decrease in response to angiotensin II or norepinephrine-induced acute hypertension. *Am J Physiol Renal Physiol* 2006;291:F952–F959. [PubMed: 16788141]
50. Ishikawa S, Schrier RW. Effect of arginine vasopressin antagonist on renal water excretion in glucocorticoid and mineralocorticoid deficient rats. *Kidney Int* 1982;22:587–593. [PubMed: 7162034]
51. Ufferman RC, Schrier RW. Importance of sodium intake and mineralocorticoid hormone in the impaired water excretion in adrenal insufficiency. *J Clin Invest* 1972;57(7):1639–1646. [PubMed: 5032519]
52. Ohara M, Cadnapaphornchai MA, Summer S, Falk S, Yang J, Togawa T, Schrier RW. Effect of mineralocorticoid deficiency on ion and urea transporters and aquaporin water channels in the rat. *Biochem Biophys Res Commun* 2002;299:285–290.
53. Chen YOC, Cadnapaphornchai MA, Summer S, Falk S, Li C, Wang W, Schrier RW. Molecular mechanisms of impaired urinary concentrating ability in glucocorticoid-deficient rats. *J Am Soc Nephrol* 2005;16:2864–2871. [PubMed: 16107579]
54. Agus Z, Goldberg M. Role of antidiuretic hormone in the abnormal water diuresis of anterior hypopituitarism in man. *J Clin Invest* 1971;50(7):1478–1489. [PubMed: 5090063]
55. Kim J, Summer S, Wood W, Schrier RW. Role of glucocorticoid hormones in arginine vasopressin gene regulation. *Biochem Biophys Res Commun* 2001;289:1252–1256. [PubMed: 11741329]
56. Wang W, Li C, Summer S, Falk S, Cadnapaphornchai MA, Chen Y-C, Schrier RW. Molecular analysis of impaired urinary diluting capacity in glucocorticoid deficiency. *Am J Physiol Renal Physiol* 2006;290:F1135–F1142. [PubMed: 16352742]

Outer and inner medullary collecting duct

Figure 1.

The intracellular action of the antidiuretic hormone, arginine-vasopressin. Used with permission from ref. 7.

Figure 2.

Figure 2A and B. Clinical conditions in which a decrease in cardiac output (A) and systemic arterial vasodilation (B) causes arterial underfilling with resultant neurohumoral activation and renal sodium and water retention. In addition to activating the neurohumoral axis, adrenergic stimulation causes renal vasoconstriction and enhances sodium and fluid transport by the proximal tubule epithelium. Reprinted with permission from ref. 28.

Figure 3. Protein expression of inner medullary AQP2 in pregnancy. Used with permission from ref. 37

Figure 4.
Reversal of Impaired Water Excretion During Hypothyroidism (HT) with V2 Receptor Antagonist (V2A), Used with permission from ref. 44.

Figure 5. Effect of V2 receptor antagonist (OPC) in glucocorticoid-deficient rats to reverse the impaired water excretion (A) and urinary dilution (B) as well as the increased AQP2 (C) and phosphorylated AQP2 expression (D). Reprinted with permission from ref. 50.

Table 1**Vasopressin Receptor Antagonists**

	Company	Approval Stage	Description/mode of administration	Purpose
Satavaptan (SR-121463)	Sanofi-Synthelabo	Phase III	Vasopressin V2 receptor antagonist Selective, orally active, non-peptide	Euvoletic and hypervolemic ^a hyponatremia
Lixivaptan (VPA-985)	Cardiokine	Phase III	Vasopressin V2 receptor antagonist Selective, orally active, non-peptide	Euvoletic and hypervolemic hyponatremia
Tolvaptan (OPC-41061)	Otsuka Pharmaceutical	Phase III	Vasopressin V2 receptor antagonist Selective, orally active, non-peptide	Euvoletic and hypervolemic hyponatremia
Conivaptan (YM-087) Vaprisol®	Astellas	Approved	Vasopressin V1 and V2 receptor antagonist Non-selective, I.V. limited to 4 days	Euvoletic hyponatremia and cardiac failure
Mozavaptan, (OPC-31260) Physuline®	Otsuka Pharmaceutical	Approved	Vasopressin V2 receptor antagonist Selective, orally active, non-peptide	Paraneoplastic SIADH ^b

^a Syndrome antidiuretic hormone secretion (SIADH) – euvoletic hyponatremia (near normal total body sodium without edema)

^b Cirrhosis and heart failure – hypervolemic hyponatremia (an increase in total body sodium, causing edema)

Used with permission of ref. 11